Healthcare
Silo Pharma, Inc.(SILO)
Live Price
Offline$6.12
+5.34% today
1Y Change
-30.02%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +58.0%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Silo Pharma, Inc. (SILO) is a Healthcare stock with listed on NASDAQ. The stock last traded around $6.12 and down 30.0% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +58.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +58.0%, free cash flow -21.6% with operating margin -5937.0% and ROIC -61.5%. Valuation already assumes a fairly strong business story at price/sales 50.3. Stock Foundry combines SILO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-5937.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +58.0%, while operating margin sits near -5937.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | โ | -3.7% | -1.2% | +3.0% |
2026 Mar 27, 2026 | โ | +0.9% | +4.7% | +28.8% |
2025 Nov 13, 2025 | โ | -5.1% | -16.3% | -0.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SILO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SILO Max Drawdown
-65.52%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SILO and SPY.
Company Overview
Silo Pharma, Inc.
NASDAQ Capital Market
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
- Leadership
- Eric Weisblum
- IPO Date
- Jan 8, 2021
- Employees
- 3
- Street Address
- 677 N. Washington Boulevard
- Mailing
- Sarasota, FL, 34236
- Region
- Sarasota, FL, US
- Reporting Currency
- USD
- Investor Line
- 718 400 9031
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.3
- Price/Sales
- 50.3
- Price/Book
- 1.0
Growth
- Revenue
- 0.0%
- EPS
- +58.0%
- Free Cash Flow
- -21.6%
Profitability
- Gross Margin
- -602.8%
- Operating Margin
- -5937.0%
- Net Margin
- -5863.5%
- ROE
- -83.5%
- ROIC
- -61.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 11.36
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.